Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide
Summary
As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX) remained strongly bullish.
Description
As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX) remained strongly bullish.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source